68Ga-and 177Lu-labeled PSMA i and T: Optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies

Journal of Nuclear Medicine

Volumn 56, Issue 8, 2015, Pages 1169-1176

  Weineisen, Martina ^a   Schottelius, Margret ^a   Simecek, Jakub ^a,b   Baum, Richard P ^c   Yildiz, Akin ^d   Beykan, Seval ^e   Kulkarni, Harshad R ^c   Lassmann, Michael ^e   Klette, Ingo ^c   Eiber, Matthias ^f   Schwaiger, Markus ^f   Wester, Hans Jürgen ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b SCINTOMICS GMBH   (Germany)

^c ZENTRALKLINIK BAD BERKA   (Germany)

^d Medstar Hospital Cancer Center   (Turkey)

^e UNIVERSITY OF WÜRZBURG   (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

177Lu; 68Ga; Prostate cancer; Prostate specific membrane antigen; PSMA I and T

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1 (GLUTAMIC ACID) 4,7,10 TRIACETIC ACID; ACETIC ACID DERIVATIVE; GALLIUM 68; LUTETIUM 177; PROSTATE SPECIFIC MEMBRANE ANTIGEN; UNCLASSIFIED DRUG; ACID ANHYDRIDE; CONTRAST MEDIUM; DOTAGA-ANHYDRIDE; GALLIUM; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; LUTETIUM; MEMBRANE ANTIGEN; SINGLE HETEROCYCLIC RINGS;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KINETICS; MALE; METASTASIS; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; SOLID; AGED; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; CHEMISTRY; DIAGNOSTIC USE; IC50; METABOLISM; MIDDLE AGED; PROSTATE TUMOR; RADIOMETRY; RADIOTHERAPY; SCINTISCANNING; TUMOR CELL LINE;

AGED; ANHYDRIDES; ANIMALS; ANTIGENS, SURFACE; CELL LINE, TUMOR; CONTRAST MEDIA; FEMALE; GALLIUM RADIOISOTOPES; GLUTAMATE CARBOXYPEPTIDASE II; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; LUTETIUM; MALE; MICE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOMETRY; RADIOTHERAPY;

EID: 84938833007     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.158550     Document Type: Article

References (37)

1. Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scinti-graphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273-282.
2. Reubi JC, Laissue J, Krenning E, Lamberts SW. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J Steroid Biochem Mol Biol. 1992;43:27-35.
3. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81-85.
4. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node me-tastases. Urology. 1998;52:637-640.
5. 11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALA-Dase). Mol Imaging. 2002;1:96-101.
6. Foss CA, Mease RC, Fan H, et al. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res. 2005;11:4022-4028.
7. 18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res. 2008;14:3036-3043.
8. 99mTc-radioimaging agents. Mol Pharm. 2009;6:790-800.
9. Hillier SM, Maresca KP, Femia FJ, et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009;69:6932-6940.
10. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem. 2010;53:5333-5341.
11. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688-697.
12. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J Nucl Med. 2013;54:1369-1376.
13. Weineisen M, Simecek J, Schottelius M, Schwaiger M, Wester H-J. Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. EJNMMI Research. 2014;4:63.
14. 68Ga] gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486-495.
15. Barrett JA, Coleman RE, Goldsmith SJ, et al. First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer. J Nucl Med. 2013;54:380-387.
16. 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med. 2012;53:1883-1891.
17. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistri-bution studies in healthy subjects and patients with metastatic prostate cancer. J Nucl Med. 2014;55:1791-1798.
18. Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer: part 1-screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59:61-71.
19. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294:238-244.
20. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213-223.
21. Sodee DB, Malguria N, Faulhaber P, Resnick MI, Albert J, Bakale G. Multicen-ter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers. Urology. 2000;56:988-993.
22. Liu H, Moy P, Kim S, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 1997;57:3629-3634.
23. 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J Nucl Med. 2005;46:850-858.
24. Tagawa ST, Milowsky MI, Morris M, et al. Phase II study of lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19:5182-5191.
25. Kulkarni H, Weineisen M, Mueller D, et al. First clinical results with Lu-177 PSMA-TUM1 for the treatment of castrate-resistant metastatic prostate cancer [abstract]. J Nucl Med. 2014;55(suppl 1):10.
26. Schuchardt C, Weineisen M, Wiessalla S, et al. Biodistribution and dosimetry of Lu-177 PSMA in metastasized castrate resistant prostate cancer patients [abstract]. J Nucl Med. 2014;55(suppl 1):641.
27. Zhang AX, Murelli RP, Barinka C, et al. A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules. J Am Chem Soc. 2010;132:12711-12716.
28. Kletting P, Schimmel S, Kestler HA, et al. Molecular radiotherapy: the NUKFIT software for calculating the time-integrated activity coefficient. Med Phys. 2013;40:102504.
29. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027.
30. 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11-20.
31. 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41:1280-1292.
32. Eder M, Schafer M, Bauder-Wust U, Haberkorn U, Eisenhut M, Kopka K. Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer. Prostate. 2014;74:659-668.
33. O'Keefe DS, Bacich DJ, Heston WD. Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene. Prostate. 2004;58:200-210.
34. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res. 1994;54:1807-1811.
35. Sparks RB, Aydogan B. Comparison of the effectiveness of some common animal data scaling techniques in estimating human radiation dose. In: Stetson A, Stabin M, Sparks R, eds. Sixth International Radiopharmaceutical Dosimetry Symposium. Oak Ridge, TN: Oak Ridge Associated Universities; 1999:705-716.
36. Pinto JT, Suffoletto BP, Berzin TM, et al. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res. 1996;2:1445-1451.
37. Perner S, Hofer MD, Kim R, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007;38:696-701.